Screener / SEC EDGAR /CIK 0001756262 /10-K filed Feb 24, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Devices

TransMedics Group, Inc. TMDX

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 24, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+436.6%

The MD&A has no sentence that names a cause for this change.

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+295.1%

The MD&A has no sentence that names a cause for this change.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

8.5% to 17.9% (+9.4 pts)

The MD&A has no sentence that names a cause for this change.

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+37.1%

“Revenue from customers in the United States related to OCS transplant was $584.7 million in the year ended December 31, 2025 and increased by $162.8 million compared to the year ended December 31, 2024, primarily due to higher sales volumes of our OCS Liver and OCS Heart disposable sets.”

Read it in the 10-K

Gross margin

Change, FY to Dec 31, 2025 vs Dec 31, 2024

59.4% to 59.9% (+0.6 pts)

The MD&A has no sentence that names a cause for this change.

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +37.1%

    “Revenue from customers in the United States related to OCS transplant was $584.7 million in the year ended December 31, 2025 and increased by $162.8 million compared to the year ended December 31, 2024, primarily due to higher sales volumes of our OCS Liver and OCS Heart disposable sets.”

    Read it in the FY 2025 10-K
  • FY 2024 +82.7%

    “Revenue from customers in the United States related to OCS transplant was $421.9 million in the year ended December 31, 2024 and increased by $200.5 million compared to the year ended December 31, 2023, primarily due to higher sales volumes of our OCS Liver and OCS Heart disposable sets.”

    Read it in the FY 2024 10-K

Gross margin

1 of 2 years explained
  • FY 2025 +0.6 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 -4.4 pts

    “The decrease in gross margin from 2023 to 2024 was driven primarily by an increase in service revenue, which has a lower gross margin than product revenue.”

    Read it in the FY 2024 10-K

    “The increase in product gross margin was primarily as a result of increased sales volume and increased sales of higher margin OCS disposable sets.”

    Read it in the FY 2024 10-K

Operating margin

1 of 2 years explained
  • FY 2025 +9.4 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +20.4 pts

    “Total selling, general and administrative expenses increased by $49.1 million from $119.6 million in the year ended December 31, 2023 to $168.6 million in the year ended December 31, 2024 due primarily to increases in personnel related costs, and facility related and other costs.”

    Read it in the FY 2024 10-K

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TMDX/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.